Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
CosentyxⓇ grew 21% in Q2, momentum expected to continue
through 2021
Sales evolution
USD m, % cc
Ex-US
US
944
330
614
+21%
Double-digit growth expected to continue in H2
■
US: growing volume in line with market across indications (vs. Q1)
1,175
460
■ EU: leading biologic in PsO, leading originator biologic in SpA¹
■
Growth continues in other markets including China post-NRDL
LCM continues to reinforce differentiated efficacy and safety
US Ped PSO approved
EU/US submitted for jPsA & ERA
■ Ph3 readout for Hidradenitis Suppurativa on track for H2 2021
715
■
US 300mg autoinjector approval expected H2 2021
■
PSO dose flexibility approval expected H2 2021 EU / H1 2022 US
Q2 2020
Q2 2021
NRDL National Reimbursement Drug List Ped PSO Pediatric Psoriasis PsO - Psoriasis SpA - Spondyloarthritis jPSA - Juvenile psoriasis arthritis ERA - Enthesitis related rheumatoid arthritis 1. TRX - EU data March 2021.
20 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation